MDCX vs. MRK
MDCX (Medicus Pharma Ltd) and MRK (Merck & Co., Inc.) are both stocks. Both are in the Healthcare sector — MDCX in Biotechnology, MRK in Drug Manufacturers - General. Over the past year, MDCX returned -81.97% vs 51.19% for MRK. At a 0.07 correlation, their price movements are largely independent.
Performance
MDCX vs. MRK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDCX achieves a -70.65% return, which is significantly lower than MRK's 11.50% return.
MDCX
- 1D
- -1.86%
- 1M
- 49.67%
- YTD
- -70.65%
- 6M
- -71.22%
- 1Y
- -81.97%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
MRK
- 1D
- 1.41%
- 1M
- -4.83%
- YTD
- 11.50%
- 6M
- 12.07%
- 1Y
- 51.19%
- 3Y*
- 3.45%
- 5Y*
- 12.33%
- 10Y*
- 11.42%
MDCX vs. MRK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
MDCX Medicus Pharma Ltd | -70.65% | -37.04% | -21.61% |
MRK Merck & Co., Inc. | 11.50% | 9.79% | 1.80% |
Correlation
The correlation between MDCX and MRK is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Nov 14, 2024 | 0.07 |
Fundamentals
MDCX:
-$1.93
MRK:
$3.58
MDCX:
$0.00
MRK:
$65.59B
MDCX:
$0.00
MRK:
$49.79B
MDCX:
-$36.18M
MRK:
$22.69B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDCX vs. MRK — Risk / Return Rank
MDCX
MRK
MDCX vs. MRK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDCX | MRK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.55 | ||
| Sortino ratioReturn per unit of downside risk | -3.70 | ||
| Omega ratioGain probability vs. loss probability | 0.88 | 1.33 | -0.45 |
| Calmar ratioReturn relative to maximum drawdown | -0.89 | 4.53 | -5.42 |
| Martin ratioReturn relative to average drawdown | -1.37 | 11.16 | -12.53 |
Loading charts...
Drawdowns
MDCX vs. MRK - Drawdown Comparison
The maximum MDCX drawdown since its inception was -96.47%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for MDCX and MRK.
Loading charts...
Drawdown Indicators
| MDCX | MRK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.47% | -68.61% | -27.86% |
Max Drawdown (1Y)Largest decline over 1 year | -91.91% | -11.37% | -80.54% |
Max Drawdown (3Y)Largest decline over 3 years | — | -43.44% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -43.44% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -43.44% | — |
Current DrawdownCurrent decline from peak | -94.23% | -7.06% | -87.17% |
Average DrawdownAverage peak-to-trough decline | -57.66% | -18.83% | -38.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 59.85% | 4.60% | +55.25% |
Volatility
MDCX vs. MRK - Volatility Comparison
Medicus Pharma Ltd (MDCX) has a higher volatility of 35.89% compared to Merck & Co., Inc. (MRK) at 9.78%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDCX | MRK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 35.89% | 9.78% | +26.11% |
Volatility (6M)Calculated over the trailing 6-month period | 119.19% | 18.13% | +101.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 126.68% | 27.15% | +99.53% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 131.88% | 23.72% | +108.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 131.88% | 22.96% | +108.92% |
Dividends
MDCX vs. MRK - Dividend Comparison
MDCX has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 3.07%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDCX Medicus Pharma Ltd | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRK Merck & Co., Inc. | 3.07% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
Financials
MDCX vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Medicus Pharma Ltd and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDCX and MRK have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDCX has higher volatility (35.89%) compared to MRK (9.78%). In terms of maximum drawdown, MDCX dropped -96.47% vs MRK's -68.61%.
MRK currently has the higher Sharpe Ratio (1.90 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDCX and MRK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer